Jump Financial’s Axsome Therapeutics AXSM Stock Holding History

Jump Financial’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25,000	Closed	-$3.04M	–	1932
2025 Q3	$3.04M	Sell	25,000 -103,500	-81%	-$11.7M	0.04%	569
2025 Q2	$13.4M	Buy	128,500 +35,860	+39%	+$3.8M	0.15%	171
2025 Q1	$10.8M	Buy	+92,640	New	+$10.6M	0.15%	168
2024 Q4	–	Sell	-9,080	Closed	-$816K	–	1642
2024 Q3	$816K	Sell	9,080 -18,039	-67%	-$1.57M	0.02%	884
2024 Q2	$2.18M	Buy	+27,119	New	+$2.01M	0.04%	515
2024 Q1	–	Sell	-8,400	Closed	-$669K	–	1896
2023 Q4	$669K	Buy	+8,400	New	+$562K	0.02%	906
2023 Q3	–	Sell	-8,488	Closed	-$610K	–	1844
2023 Q2	$610K	Sell	8,488 -51,503	-86%	-$3.8M	0.02%	932
2023 Q1	$3.7M	Buy	59,991 +27,241	+83%	+$1.79M	0.15%	217
2022 Q4	$2.53M	Sell	32,750 -4,636	-12%	-$277K	0.13%	202
2022 Q3	$1.67M	Buy	+37,386	New	+$1.87M	0.06%	432
2021 Q2	–	Sell	-12,500	Closed	-$708K	–	1077
2021 Q1	$708K	Buy	+12,500	New	+$879K	0.07%	311

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jump Financial's AXSM Position: Q4 2025 in Review

Jump Financial sold out of Axsome Therapeutics (AXSM) in Q4 2025, closing a stake of 25,000 shares — an estimated $3.04M sold.

Jump Financial first reported a position in AXSM in Q1 2021 and held it in 11 quarters. The position peaked at $13.4M in Q2 2025. 398 funds tracked by Wall St. Rank hold AXSM as of Q4 2025.

Jump Financial reported no remaining Axsome Therapeutics position as of Q4 2025 after selling out during the quarter.
Jump Financial sold 25,000 Axsome Therapeutics shares in Q4 2025, an estimated $3.04M.
Jump Financial first reported a position in Axsome Therapeutics in Q1 2021 and held it in 11 quarters.
Jump Financial's Axsome Therapeutics position peaked at $13.4M in Q2 2025.
398 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2025.

Based on Jump Financial's 13F filing for Q4 2025, filed 17 Feb 2026.